Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

A clinical study of Cerebral Venous Thrombosis (CVT).

Kota VS, Latha Devi GS.

J Assoc Physicians India. 2020 Jan;68(1):68. No abstract available.

PMID:
31979681
2.

ERRATUM: Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.

Jillella AP, Arellano ML, Heffner LT, Gaddh M, Langston AA, Khoury HJ, Mangaonkar A, Kota VK.

Hematol Rep. 2019 Dec 4;11(4):8395. doi: 10.4081/hr.2019.8395. eCollection 2019 Nov 29. No abstract available.

3.

Rectovaginal Fistula as a Complication of Fecal Management System.

Butts E, Padala SA, Vakiti A, Kota V.

J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619869368. doi: 10.1177/2324709619869368.

4.

Identification and Clinical Validation of a Novel 4 Gene-Signature with Prognostic Utility in Colorectal Cancer.

Ahluwalia P, Mondal AK, Bloomer C, Fulzele S, Jones K, Ananth S, Gahlay GK, Heneidi S, Rojiani AM, Kota V, Kolhe R.

Int J Mol Sci. 2019 Aug 5;20(15). pii: E3818. doi: 10.3390/ijms20153818.

5.

Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA.

Bolds SL, Hassan SMK, Caprara CR, Debragga S, Simon KS, Karkhanis P, Gandhi A, Jillella AP, Kota V.

Hematol Rep. 2019 May 23;11(2):7896. doi: 10.4081/hr.2019.7896. eCollection 2019 May 23.

6.

Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation.

Kota V, Atallah E.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):480-487. doi: 10.1016/j.clml.2019.05.007. Epub 2019 May 13. Review.

7.

Patients' perspectives on the definition of cure in chronic myeloid leukemia.

Flynn KE, Mauro MJ, George G, Hinman A, Baim A, Kota V, Larson RA, Lipton JH, Thompson JE, Wadleigh M, Atallah E.

Leuk Res. 2019 May;80:40-42. doi: 10.1016/j.leukres.2019.03.007. Epub 2019 Mar 28. No abstract available.

PMID:
30955853
8.

A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.

Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV, Kota VK.

Leuk Res. 2019 Mar;78:45-51. doi: 10.1016/j.leukres.2019.01.008. Epub 2019 Jan 24.

9.

A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.

Hassankrishnamurthy S, Mody MD, Kota VK.

Am J Case Rep. 2019 Jan 3;20:10-14. doi: 10.12659/AJCR.911854.

10.

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.

Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, Gambacorti-Passerini C.

J Hematol Oncol. 2018 Dec 27;11(1):143. doi: 10.1186/s13045-018-0685-2. Review.

11.

Feasibility and Safety of Split-Liver Transplantation in a Nascent Framework of Deceased Donation.

Cherukuru R, Reddy MS, Shanmugam NP, Rajalingam R, Kota V, Gunasekaran V, Narasimhan G, Kaliamoorthy I, Rela M.

Liver Transpl. 2019 Mar;25(3):450-458. doi: 10.1002/lt.25405.

PMID:
30586233
12.

Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL.

Kim C, Molony JT, Chia VM, Kota VK, Katz AJ, Li S.

Leuk Lymphoma. 2019 Jun;60(6):1462-1468. doi: 10.1080/10428194.2018.1538505. Epub 2018 Dec 13.

PMID:
30541363
13.

A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.

Guddati AK, Kota V.

N Engl J Med. 2018 Nov 8;379(19):1879. doi: 10.1056/NEJMc1811050. No abstract available.

PMID:
30406979
14.

Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.

Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV, Kota V.

Leuk Res. 2018 Aug;71:27-33. doi: 10.1016/j.leukres.2018.06.010. Epub 2018 Jun 18.

15.

Child Syndrome.

Ramphul K, Kota V, Mejias SG.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-.
2019 Jun 4.

16.

Rhabdomyolysis Following Initiation of Antiviral Therapy with Oseltamivir.

Puttagunta H, Alghsoon S, Regula P, Hassankrishnamurthy S, Kota VK.

Am J Case Rep. 2018 Jun 11;19:673-677. doi: 10.12659/AJCR.909278.

17.

Defining ICR-Mo, an intrinsic colistin resistance determinant from Moraxella osloensis.

Wei W, Srinivas S, Lin J, Tang Z, Wang S, Ullah S, Kota VG, Feng Y.

PLoS Genet. 2018 May 14;14(5):e1007389. doi: 10.1371/journal.pgen.1007389. eCollection 2018 May.

18.

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.

Khoury HJ, Langston AA, Kota VK, Wilkinson JA, Pusic I, Jillella A, Bauer S, Kim AS, Roberts D, Al-Kadhimi Z, Bodo I, Winton E, Arellano M, DiPersio JF.

Bone Marrow Transplant. 2018 Jul;53(7):826-831. doi: 10.1038/s41409-017-0081-5. Epub 2018 Jan 24.

19.

Birth preparedness and complication readiness in pregnant women attending urban tertiary care hospital.

Kamineni V, Murki AD, Kota VL.

J Family Med Prim Care. 2017 Apr-Jun;6(2):297-300. doi: 10.4103/2249-4863.220006.

20.

SUMO Modification of the RNA-Binding Protein La Regulates Cell Proliferation and STAT3 Protein Stability.

Kota V, Sommer G, Hazard ES, Hardiman G, Twiss JL, Heise T.

Mol Cell Biol. 2017 Dec 29;38(2). pii: e00129-17. doi: 10.1128/MCB.00129-17. Print 2018 Jan 15.

21.

Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.

Jillella AP, Arellano ML, Heffner LT, Gaddh M, Langston AA, Khoury HJ, Mangoankar A, Kota VK.

Hematol Rep. 2017 Sep 26;9(3):7083. doi: 10.4081/hr.2017.7083. eCollection 2017 Sep 26. No abstract available.

22.

A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression.

Mangaonkar A, Mondal AK, Fulzule S, Pundkar C, Park EJ, Jillella A, Kota V, Xu H, Savage NM, Shi H, Munn D, Kolhe R.

Sci Rep. 2017 Oct 16;7(1):12892. doi: 10.1038/s41598-017-12940-0.

23.

The global problem of early deaths in acute promyelocytic leukemia: A strategy to decrease induction mortality in the most curable leukemia.

Jillella AP, Kota VK.

Blood Rev. 2018 Mar;32(2):89-95. doi: 10.1016/j.blre.2017.09.001. Epub 2017 Sep 18. Review.

PMID:
29033137
24.

Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib.

Kota VK, Kong JH, Arellano M, El Rassi F, Gaddh M, Heffner LT, Winton EF, Jillella AP, McLemore ML, Khoury HJ.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e71-e73. doi: 10.1016/j.clml.2017.09.004. Epub 2017 Sep 19.

PMID:
29032022
25.

The safety of Bosutinib for the treatment of chronic myeloid leukemia.

Kong JH, Khoury HJ, Kim AS, Hill BG, Kota V.

Expert Opin Drug Saf. 2017 Oct;16(10):1203-1209. doi: 10.1080/14740338.2017.1363176. Epub 2017 Sep 5. Review.

PMID:
28774214
26.

Varicella (Chickenpox) Vaccine.

Kota V, Lenehan CP, Grella MJ.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-.
2019 Dec 11.

27.

Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis.

Lin H, Ding Z, Kota VG, Zhang X, Zhou J.

Oncotarget. 2017 Jul 11;8(28):46601-46610. doi: 10.18632/oncotarget.16662. Review.

28.

Applying a high-throughput fluorescence polarization assay for the discovery of chemical probes blocking La:RNA interactions in vitro and in cells.

Sommer G, Fedarovich A, Kota V, Rodriguez R, Smith CD, Heise T.

PLoS One. 2017 Mar 14;12(3):e0173246. doi: 10.1371/journal.pone.0173246. eCollection 2017.

29.

Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?

Kong JH, Winton EF, Heffner LT, Chen Z, Langston AA, Hill B, Arellano M, El-Rassi F, Kim A, Jillella A, Kota VK, Bodó I, Khoury HJ.

Cancer. 2017 Jul 1;123(13):2482-2488. doi: 10.1002/cncr.30608. Epub 2017 Feb 27.

30.

Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia: A Case Report.

Mody MD, Ravindranathan D, Gill HS, Kota VK.

J Investig Med High Impact Case Rep. 2017 Feb 1;5(1):2324709617690747. doi: 10.1177/2324709617690747. eCollection 2017 Jan-Mar.

31.

Changing pattern of biliary complications in an evolving liver transplant unit.

Rammohan A, Govil S, Vargese J, Kota V, Reddy MS, Rela M.

Liver Transpl. 2017 Apr;23(4):478-486. doi: 10.1002/lt.24736.

32.

Long-term health-related quality of life in living liver donors: A south Asian experience.

Cherian PT, Mishra AK, Mahmood SM, Sathyanarayanan M, Raya R, Kota V, Rela MS.

Clin Transplant. 2017 Mar;31(3). doi: 10.1111/ctr.12882. Epub 2017 Feb 15.

PMID:
27935642
33.

Recurrent Parotid Carcinosarcoma in an Asymptomatic Patient.

Mansour J, Mangaonkar A, Kota V.

J Investig Med High Impact Case Rep. 2016 Nov 4;4(4):2324709616676590. eCollection 2016 Oct-Dec.

34.

Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.

Winton EF, Kota V.

Future Oncol. 2017 Feb;13(5):395-407. doi: 10.2217/fon-2016-0417. Epub 2016 Oct 27. Review.

PMID:
27785927
35.

Multidisciplinary management of hepatoblastoma in children: Experience from a developing country.

Shanmugam N, Scott JX, Kumar V, Vij M, Ramachandran P, Narasimhan G, Reddy MS, Kota V, Munirathnam D, Kelgeri C, Sundaram K, Rela M.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26249. Epub 2016 Oct 26.

PMID:
27781375
36.

Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?

DeFilipp Z, Langston AA, Chen Z, Zhang C, Arellano ML, El Rassi F, Flowers CR, Kota VK, Al-Kadhimi Z, Veldman R, Jillella AP, Lonial S, Waller EK, Khoury HJ.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):466-471.e1. doi: 10.1016/j.clml.2016.04.017. Epub 2016 May 5.

PMID:
27297665
37.

SUMO-Modification of the La Protein Facilitates Binding to mRNA In Vitro and in Cells.

Kota V, Sommer G, Durette C, Thibault P, van Niekerk EA, Twiss JL, Heise T.

PLoS One. 2016 May 25;11(5):e0156365. doi: 10.1371/journal.pone.0156365. eCollection 2016.

38.

Donor Outcomes in Living Donor Liver Transplantation-Analysis of 275 Donors From a Single Centre in India.

Narasimhan G, Safwan M, Kota V, Reddy MS, Bharathan A, Dabora A, Kaliamoorthy I, Kanagavelu RG, Srinivasan V, Rela M.

Transplantation. 2016 Jun;100(6):1251-6. doi: 10.1097/TP.0000000000001246.

PMID:
27203592
39.

Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.

Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1348-1356. doi: 10.1016/j.bbmt.2016.04.018. Epub 2016 Apr 27. No abstract available.

40.

Complete Remission of Acute Myeloid Leukemia following Cisplatin Based Concurrent Therapy with Radiation for Squamous Cell Laryngeal Cancer.

Mody MD, Gill HS, Higgins KA, Saba NF, Kota VK.

Case Rep Hematol. 2016;2016:8581421. doi: 10.1155/2016/8581421. Epub 2016 Apr 3.

41.

The La protein counteracts cisplatin-induced cell death by stimulating protein synthesis of anti-apoptotic factor Bcl2.

Heise T, Kota V, Brock A, Morris AB, Rodriguez RM, Zierk AW, Howe PH, Sommer G.

Oncotarget. 2016 May 17;7(20):29664-76. doi: 10.18632/oncotarget.8819.

42.

Liver transplantation in India.

Narasimhan G, Kota V, Rela M.

Liver Transpl. 2016 Jul;22(7):1019-24. doi: 10.1002/lt.24459.

43.

Prognostic value of complete remission with superior platelet counts in acute myeloid leukemia.

Mangaonkar A, Xu H, Mohsin J, Mansour J, Chintalapally R, Keen R, Mondal AK, DeRemer D, Clemmons AB, Clark SM, Shah A, Jillela A, Kolhe R, Kota V.

J Community Support Oncol. 2016 Feb;14(2):66-71. doi: 10.12788/jcso.0231.

PMID:
26955659
44.

Safety of Live Liver Donation by Individuals With G6PD Deficiency: Initial Results and Comparative Study.

Reddy MS, Shrivastav M, Kaliamoorthy I, Kota V, Dabora A, Govil S, Rela M.

Transplantation. 2016 Apr;100(4):814-8. doi: 10.1097/TP.0000000000001053.

PMID:
26760569
45.

Pneumatosis Intestinalis in a Patient with Acute Promyelocytic Leukemia.

Mangaonkar A, Mansour J, Keen R, Kukkadapu T, Chintalapally R, Kota V.

Case Rep Hematol. 2015;2015:576042. doi: 10.1155/2015/576042. Epub 2015 Oct 8.

46.

Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients.

Hartranft ME, Clemmons AB, DeRemer DL, Kota V.

J Oncol Pharm Pract. 2017 Jan;23(1):10-17. doi: 10.1177/1078155215612240. Epub 2016 Jun 22.

PMID:
26471738
47.

Volasertib for AML: clinical use and patient consideration.

Hao Z, Kota V.

Onco Targets Ther. 2015 Jul 17;8:1761-71. doi: 10.2147/OTT.S60762. eCollection 2015. Review.

48.

Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.

Clark SM, Clemmons AB, Schaack L, Garren J, DeRemer DL, Kota VK.

J Oncol Pharm Pract. 2016 Jun;22(3):416-22. doi: 10.1177/1078155215585190. Epub 2015 May 7.

PMID:
25956421
49.

Congestive heart failure during induction with anthracycline-based therapy in patients with acute promyelocytic leukemia.

Kota V, Clemmons A, Chand A, Simmons J, Mansour J, Kolhe R, Jillella A.

J Community Support Oncol. 2014 Nov;12(11):390-3. doi: 10.12788/jcso.0084.

PMID:
25856011
50.

Better innovate than compromise: a novel hepatic outflow reconstruction technique in pediatric living donor liver transplantation.

Cherian PT, Mishra AK, Bangaari A, Kota V, Sathyanarayanan M, Raya R, Rela M.

Pediatr Transplant. 2015 May;19(3):E56-61. doi: 10.1111/petr.12437. Epub 2015 Feb 6.

PMID:
25655683

Supplemental Content

Support Center